Rhythm Pharmaceuticals (NASDAQ:RYTM) & Alzamend Neuro (NASDAQ:ALZN) Head-To-Head Comparison

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Alzamend Neuro (NASDAQ:ALZN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Insider & Institutional Ownership

49.6% of Alzamend Neuro shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by insiders. Comparatively, 1.4% of Alzamend Neuro shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Rhythm Pharmaceuticals and Alzamend Neuro, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1	2	14	1	2.83
Alzamend Neuro	1	0	1	0	2.00

Rhythm Pharmaceuticals presently has a consensus price target of $133.13, suggesting a potential upside of 20.98%. Alzamend Neuro has a consensus price target of $28.00, suggesting a potential upside of 2,313.79%. Given Alzamend Neuro’s higher probable upside, analysts clearly believe Alzamend Neuro is more favorable than Rhythm Pharmaceuticals.

Earnings and Valuation

This table compares Rhythm Pharmaceuticals and Alzamend Neuro”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76 million	39.74	-$196.54 million	($3.13)	-35.16
Alzamend Neuro	N/A	N/A	-$4.51 million	($2.16)	-0.54

Alzamend Neuro has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Rhythm Pharmaceuticals has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Comparatively, Alzamend Neuro has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500.

Profitability

This table compares Rhythm Pharmaceuticals and Alzamend Neuro’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Alzamend Neuro	N/A	-177.52%	-140.41%

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

About Alzamend Neuro

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.